Does tacrolimus, in comparison with sirolimus, increase mycophenolic acid exposure in kidney transplant recipients?
Picard
N
N
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D016030:Kidney Transplantation / Q000379:methods; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D020123:Sirolimus / Q000494:pharmacology*; D016559:Tacrolimus / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus
Ther Drug Monit. 2008 Dec;30(6):656-61
18978521
Ther Drug Monit. 2001 Apr;23(2):119-28
11294511
Clin Pharmacol Ther. 2009 Oct;86(4):411-5
19606088
Clin Pharmacol Ther. 2010 Jan;87(1):100-8
19890249
Transplant Proc. 2000 Nov;32(7):2536
11120282